Health Care & Life Sciences » Pharmaceuticals | Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals Ltd.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
30.54 M
Public Float
15.64 M
Foamix Pharmaceuticals Ltd.
Stock Exchange NASDAQ Stock Market
EPS
$1.38
Market Cap
$124.64 M
Shares Outstanding
54.37 M
Public Float
47.43 M

Profile

Address
2 Holzman Street
Rehovot HM 76704
Israel
Employees -
Website http://www.foamixpharma.com
Updated 07/08/2019
Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.

Financials

View All
Created with Highcharts 5.0.14Foamix Pharmaceuticals Ltd.Net Income. Fiscal year is January-December. All values USD Thousands.2 4312 43111 48411 48416 51716 51729 33629 33665 71565 71574 16374 163201320142015201620172018020k40k60k80k
Created with Highcharts 5.0.14Foamix Pharmaceuticals Ltd.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.1 4041 4045 4145 4148498495 5275 5273 6693 6693 5953 59520132014201520162017201801k2k3k4k5k6k

Stanley Hirsch
Chairman
David Domzalski
Chief Executive Officer & Director